Fate Therapeutics Q3 net loss widens

Fate Therapeutics

13/11/2025 13:38

Overview

Fate Therapeutics Q3 2025 revenue was $1.7 mln, a decrease from the previous year

Net loss for Q3 2025 was $32.25 mln, increasing Y/Y

Outlook

Company projects operating runway through 2027 with $226 mln in cash and investments

Fate Therapeutics plans registration study for FT819 in 2026

Company receives UK and EU regulatory authorization for FT819 clinical trials

Result Drivers

REGULATORY AUTHORIZATIONS - Fate Therapeutics received authorization from UK and EU authorities to activate ex-US clinical trial sites for FT819, expanding international reach

AUTOIMMUNE DISEASE TRIALS - FT819 showed promising clinical activity and safety in autoimmune diseases, including lupus and systemic sclerosis, with reduced conditioning requirements

SOLID TUMOR PROGRAM - FT836 targets solid tumors using Sword and Shield technology, enabling conditioning-free treatment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$1.74 mln
Q3 Net Income
-$32.25 mln
Q3 Basic EPS
-$0.27
Q3 Income from Operations
-$34.74 mln
Q3 Operating Expenses
$36.48 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Fate Therapeutics Inc is $4.50, about 76.9% above its November 12 closing price of $1.04

Press Release: ID:nGNX1FbswV

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)